A New Horizon in Liver Disease
Proceedings of the 5th International Kyoto Liver Symposium (IKLS), May 27–29, 2016, Kyoto

Guest Editors
Kwang-Hyub Han, Seoul
Masatoshi Kudo, Osaka
Sheng-Long Ye, Shanghai
Over the last decade, immuno-oncology has witnessed an astonishing pace of discovery and innovation, translating into unprecedented successes in the clinical setting, arguably representing one of the most profound and transforming revolutions in the history of cancer therapy. This book provides a concise and accurate outline of the main developments in major tumor types including melanoma, lung, breast, brain and renal cell cancers. In addition, transversal chapters that describe the commonalities of some of the therapeutic strategies are provided to cover topics like immune checkpoint biology, T cell engineering or rational combination therapies. Each chapter has been authored by senior key opinion leaders in their respective fields to provide the most up-to-date view on cancer immuno-oncology. To reflect on the key translational aspect of immuno-oncology, all chapters are making explicit connections between basic science discoveries and the resulting translational therapeutic strategies. Immuno-Oncology will be an invaluable source of information for scientists interested in the translation of basic immunology into the clinical practice, as well as for clinicians interested in deepening their knowledge of current and upcoming immune strategies in the fight against cancer.
Guidelines for Authors

Submission
Original papers and reviews written in English are considered for publication. Manuscripts should be submitted to Oncology online and must be accompanied by a cover letter signed by the submitting/corresponding author on behalf of all co-authors. Assurance should be given that the manuscript is not under simultaneous consideration by any other publication. For specific instructions on how to prepare a manuscript for submission, you are encouraged to view the guidelines at www.karger.com/ocl, where you will also find a link to the Submission Website. Names, postal and e-mail addresses of at least four experts in the appropriate area of research must accompany each manuscript. Selected scientists will be invited to act as referees. Referees suggested should not be from the same institution as the author and should have expert knowledge of the subject. Should you have any problems with your submission, please contact:

Dr. M. Markman
S. Karger AG
Editorial Office "Oncology"
CH–4009 Basel (Switzerland)
Tel. +41 61 306 1359
Fax +41 61 306 1434
E-Mail ocl@karger.com

Mailing address for courier deliveries only:
Allschwilerstr. 10
CH–4055 Basel (Switzerland)

Conditions
All manuscripts are subject to editorial review. Manuscripts are received with the explicit understanding that they are not under simultaneous consideration by any other publication. The editors reserve the right to improve style and, if necessary, return the manuscript for rewriting to the author. Submission of an article for publication implies the transfer of the copyright from the author to the publisher upon acceptance. Accepted papers become the permanent property of Oncology and may not be reproduced by any means, in whole or in part, without the written consent of the publisher. It is the author's responsibility to obtain permission to reproduce illustrations, tables, etc. from other publications.

Articles originating from non-English speaking countries must be revised by a professional linguistic reviewer and it must be evident from the covering letter that this has been done. The editor reserves the right to reject papers based on priorities and space availability in the journal.

Conflicts of Interest
Authors are required to disclose any sponsorship or funding arrangements relating to their research and all authors should disclose any possible conflicts of interest. Conflict of interest statements will be published at the end of the text of the article.

Ethical and Legal Prerequisites
Manuscripts involving examinations of human subjects must include a statement that the trial protocol has been approved by an ethical committee and thus meets the standards of the Declaration of Helsinki in its revised version of 1975 and its amendments of 1983, 1989, and 1996 [JAMA 1997;277:925–926]. Accordingly, the subject’s informed consent has to be mentioned in the manuscript. Information suitable to reveal the subject’s identity is to be avoided.

Plagiarism Policy
Whether intentional or not, plagiarism is a serious violation. We define plagiarism as a case in which a paper reproduces another work with at least 25% similarity and without citation. If evidence of plagiarism is found before/after acceptance or after publication of the paper, the author will be offered a chance for rebuttal. If the arguments are not found to be satisfactory, the manuscript will be retracted and the author sanctioned from publishing papers for a period to be determined by the responsible Editor(s).

Categories of Manuscripts
Reviews are comprehensive, state-of-the-art analyses and investigations of important clinical problems. Reviews must include a critical discussion of the reported data and give a clear conclusion with the potential impacts on the standard of care. Reviews may be invited by the Editor, or they may be unsolicited submissions. Reviews are not subject to page charges. The maximum length of manuscripts in this category will be 5,000 words for text and tables (a table = 250 words per page), with a maximum of 5 tables and 50 references.

Clinical Studies and Clinical Translational Research Articles are full-length research papers which will be considered for the journal. These articles cover topics relevant to clinical and translational studies in all oncological fields. Note that manuscripts presenting laboratory-based research efforts must address a clinically relevant issue (Translational Research).

Short Communications will focus on descriptions of important toxicities of novel therapies and highly unique oncology-related medical management issues. The maximum length of manuscripts in this category will be 1,000 words.

Clinical Trial Notes are designed for brief discussions of clinical trials, with a particular focus on phase 1, phase 1/2, and phase 2 studies. Priority in this section will not be for studies with a “positive result,” but rather for well-conceived and conducted clinical research efforts. The maximum length of manuscripts submitted in this category will be 1,500 words, with a maximum of 2 tables and 1 figure. The paper should be divided into four sections: Introduction, Methods, Results, Discussion. Note that all manuscripts submitted in this category will undergo rapid review for acceptance or rejection.

Reducing the Worldwide Burden of Cancer are country reports describing a variety of regional, national or international efforts that focus on the unique aspects of the epidemiology of cancer, and the delivery of educational messages, preventive services, and oncology-related care within the developing world. Papers submitted for this section benefit from a higher quota of free pages. There are no page charges for papers of 8 or fewer printed pages. Each additional complete or partial page is charged to the author at CHF 325.00.

Editorials are commentaries on current topics or on papers published elsewhere in the issue. Word count limit is 1,500 and 10 references are allowed. They are usually invited by the Editor.

Letters addressed to the Editor are encouraged if they directly concern articles previously published in this journal and clinical subjects related to the matters discussed. The editor reserves the right to submit copies of such letters to the authors of the articles concerned prior to publication in order to permit them to respond in the same issue of the journal. But letters on general scientific or medical subjects in oncology are also welcome. The length should not exceed 300 words.

Arrangement
Title page: The first page of each paper should indicate the title, the authors’ names, the institute where the work was conducted, and a short title for use as running head.

Full address: The exact postal address of the corresponding author complete with postal code must be given at the bottom of the title page. Please also supply phone and fax numbers, as well as e-mail address.

Key words: Please supply 3–10 key words in English that reflect the content of the paper.

Abstract: Papers submitted to the sections Reviews, Clinical Studies, Clinical Translational Research Articles, Clinical Trial Notes and Reducing the Worldwide Burden of Cancer need an abstract of up to 200 words. Abstracts are recommended, but optional, for Short Communications and Editorials. Abstracts of papers submitted for publication that have clinical implications using human materials should be structured with subheadings as follows: Objective(s), Methods, Results, Conclusion(s).

Footnotes: Avoid footnotes. When essential, they are numbered consecutively and typed at the foot of the appropriate page.

Tables and illustrations: Tables and illustrations (both numbered in Arabic numerals) should be prepared on separate pages. Tables require a heading and figures a legend, also prepared on a separate page. Due to technical reasons, figures with a screen background should not be submitted. When possible, group several illustrations in one block for reproduction (max. size 180 × 223 mm) or provide crop marks. Each illustration must be labelled with its number and the first author's name. B/w half-tone and color illustrations must have a final resolution of 300 dpi after scaling, line drawings one of 800–1,200 dpi. Figure files must not be embedded in a document file but submitted separately (see detailed instructions on the Submission Website at www.karger.com/ocl).
ISSN Print Edition: 0030–2414
ISSN Online Edition: 1423–0232

Journal Homepage: www.karger.com/ocl

Publication Data: Oncology is published 12 times a year. Volumes 92 and 93, each with 6 issues, appear in 2017.

Copyright: © 2017 S. Karger AG, Basel (Switzerland). All rights reserved. No part of this publication may be translated into other languages, reproduced or utilized in any form or by any means, electronic or mechanical, including photocopying, recording, microcopying, or by any information storage and retrieval system, without permission in writing from the publisher.

Disclaimer: The statements, opinions and data contained in this publication are solely those of the individual authors and contributors and not of the publisher and the editor(s). The appearance of advertisements in the journal is not a warranty, endorsement, or approval of the products or services advertised or of their effectiveness, quality or safety. The publisher and the editor(s) disclaim responsibility for any injury to persons or property resulting from any ideas, methods, instructions or products referred to in the content or advertisements.

Subscription Rates: Subscriptions run for a full calendar year. Prices are given per year.

Personal subscription:

Print or Online  Print+Online combined
CHF 1786.00  CHF 1886.00
EUR 1609.00  EUR 1689.00
USD 1941.00  USD 2049.00

postage and handling (added to print and print-online)

CHF 96.00, Europe, CHF 139.20 Overseas
EUR 86.40
USD 134.40

Institutional subscription:

Print or Online  Print+Online combined
CHF 3571.00  CHF 4107.00
EUR 3217.00  EUR 3700.00
USD 3882.00  USD 4464.00

postage and handling (added to print and print-online)

CHF 120.00, Europe, CHF 174.00 Overseas
EUR 108.00
USD 168.00

Back Volumes and Single Issues: Information on availability and prices of single print issues and print or electronic back volumes can be obtained from Customer Service at service@karger.com.

Bibliographic Indices: This journal is regularly listed in bibliographic services, including Current Contents® and PubMed/MEDLINE.

Subscription Orders:
Orders can be placed at agencies, bookstores, directly with the Publisher
S. Karger AG
Medical and Scientific Publishers
Allschwilerstrasse 10
CH–4009 Basel
Switzerland
t: +41 61 306 11 11
f: +41 61 306 12 34
e: karger@karger.com
w: www.karger.com
(for courier services only: Allschwilerstrasse 10
CH–4055 Basel)

Change of Address:
Both old and new address should be sent to the subscription source.

KARGER
© 2017 S. Karger AG, Basel
E-Mail karger@karger.com
www.karger.com

The Journal Home Page is available at:
www.karger.com/ocl
Contents

See the journal website for contents
This peer-reviewed online-only journal publishes original case reports covering the entire spectrum of oncology, including prevention, diagnosis, treatment, toxicities of therapy, supportive care, quality-of-life, and survivorship issues. The journal will also accept case reports dealing with the use of novel technologies, both in the arena of diagnosis and treatment. Supplementary material is welcomed. The intent of the journal is to provide clinicians and researchers with a tool to disseminate their personal experiences to a wider public as well as to review interesting cases encountered by colleagues all over the world. Universally used terms can be searched across the entire growing collection of case reports, further facilitating the retrieval of specific information.

Following the open access principle, the entire contents can be retrieved at no charge, guaranteeing easy access to this valuable source of anecdotal information at all times.

More information at www.karger.com/cro
Liver cancer has a very high prevalence among cancers in general and is one of the most common causes of death worldwide. Based on these facts, the journal *Liver Cancer* serves the growing need to better understand the causes, mechanisms and therapy of the malignancy. It provides the international community of researchers and clinicians with a platform for their research results, focusing on molecular carcinogenesis, prevention, surveillance, diagnosis and treatment, including molecular targeted therapy, of the disease. *Liver Cancer* publishes clinical and translational research related to the field of liver cancer in both humans and experimental models in the form of original and review articles.

Liver cancer has a very high prevalence among cancers in general and is one of the most common causes of death worldwide. Based on these facts, the journal *Liver Cancer* serves the growing need to better understand the causes, mechanisms and therapy of the malignancy. It provides the international community of researchers and clinicians with a platform for their research results, focusing on molecular carcinogenesis, prevention, surveillance, diagnosis and treatment, including molecular targeted therapy, of the disease. *Liver Cancer* publishes clinical and translational research related to the field of liver cancer in both humans and experimental models in the form of original and review articles.

Liver cancer has a very high prevalence among cancers in general and is one of the most common causes of death worldwide. Based on these facts, the journal *Liver Cancer* serves the growing need to better understand the causes, mechanisms and therapy of the malignancy. It provides the international community of researchers and clinicians with a platform for their research results, focusing on molecular carcinogenesis, prevention, surveillance, diagnosis and treatment, including molecular targeted therapy, of the disease. *Liver Cancer* publishes clinical and translational research related to the field of liver cancer in both humans and experimental models in the form of original and review articles.

Liver cancer has a very high prevalence among cancers in general and is one of the most common causes of death worldwide. Based on these facts, the journal *Liver Cancer* serves the growing need to better understand the causes, mechanisms and therapy of the malignancy. It provides the international community of researchers and clinicians with a platform for their research results, focusing on molecular carcinogenesis, prevention, surveillance, diagnosis and treatment, including molecular targeted therapy, of the disease. *Liver Cancer* publishes clinical and translational research related to the field of liver cancer in both humans and experimental models in the form of original and review articles.